25.01.2019 • News

Celanese Agrees Linde Syngas Deal

Celanese Agrees Linde Syngas Deal (c) Linde
Celanese Agrees Linde Syngas Deal (c) Linde

Celanese has signed a definitive agreement to buy Linde’s syngas plant in Pasadena, Texas, USA. Financial terms of the transaction, which remains subject to the usual closing conditions and regulatory approvals, were not disclosed.

Linde’s sale of the 365,000 t/y facility, which is located at Celanese’s Clear Lake acetyl intermediates complex, is part of a series of divestments that the US Federal Trade Commission (FTC) requires for approving the German gases group’s merger with Praxair.

“By acquiring this syngas production unit, Celanese will have the capability of producing a critical raw material for the world’s largest acetyl intermediates production facility,” said Todd Elliott, senior vice president, acetyls at Celanese. “Linde is currently the primary carbon monoxide supplier to the Clear Lake facility and the acquisition of this synthesis gas production unit will provide Celanese with future productivity and growth configuration options.”

In separate news, Celanese has completed its purchase of Indian engineering thermoplastic (ETP) compounder Next Polymers. Located in Mumbai, Next Polymers specializes in the custom compounding of various ETP materials and operates a 20,000 t/y plant in Silvassa in the union territory of Dadra & Nagar Haveli.

Celanese said the acquisition further expands its global manufacturing footprint, adding 10 production lines to support local customers in a fast-growing market and leverage a potential export base.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.